Pursuing this purpose, different vaccine strategies have been tested, and live attenuated vaccines and recombinant proteins are promising options. Through a process of random mutagenesis, it was identified 34 live recombinant strains of C. pseudotuberculosis [7], one of which (CZ171049, now called CP09) presented promising results in pilot trials, where inoculated mice presented no clinical signs of caseous lymphadenitis and produced a significant amount of specific IgG